Alnylam Pharmaceuticals (ALNY) PT Raised to $459 at Truist Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $161.08 --0%
Rating Summary:
26 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Rating Summary:
26 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
Truist Securities analyst Danielle Brill raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $459.00 (from $385.00) while maintaining a Buy rating.
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $199 at Bernstein SocGen Group
- Sony (SONY) PT Raised to $26 at Bernstein SocGen Group
- Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
